, Columnist
Moderna Faces Tougher Competition in Its Next Chapter
The maker of Covid vaccines will need to make the case that its flu and RSV shots offer something unique.
Covid vaccine allowed Moderna to turn a profit for the first time since its founding in 2010.
Photographer: Toru Hanai/Bloomberg
This article is for subscribers only.
Moderna Inc. made a pitch to investors this week at its annual R&D day that the unprecedented success of its Covid vaccine wasn’t a one-off, and the company is well on the way to becoming a big biotech contender.
As it evolves, the biggest challenge for Moderna has shifted from proving that its mRNA vaccines and products work to convincing the world that they offer something better than what’s already out there. That’s a tougher sell.